S. Modi, W. Jacot, T. Yamashita, J. Sohn, M. Vidal, E. Tokunaga, J. Tsurutani, N. Ueno, A. Prat, Y. Chae, K. Lee, N. Niikura, Yeon-Hee Park, Bing-he Xu, Xiao-juan Wang, M. Gil-Gil, Wei Li, J. Pierga, S. Im, H. Moore, H. Rugo, R. Yerushalmi, F. Zagouri, A. Gombos, Sung-Bae Kim, Qiang Liu, T. Luo, C. Saura, P. Schmid, T. Sun, D. Gambhire, L. Yung, Yibing Wang, Jasmeet Singh, P. Vitazka, G. Meinhardt, N. Harbeck, D. Cameron
2022.6.5NEW ENGLAND JOURNAL OF MEDICINE
tlooto Summary
In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician’s choice of chemotherapy.
Abstract
METHODS We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an IHC score of 2+ and negative results on in situ hybridization.) Patients were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan or the physician’s choice of chemotherapy. The primary end point was progression-free survival in the hormone receptor–positive cohort. The key secondary end points were progression-free survival among all patients and overall survival in the hormone receptor–positive cohort and among all patients.
Citation format
MODI, S., et al. Trastuzumab deruxtecan in previously treated her2-low advanced breast cancer. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387: 9–20.